2022年中欧和东欧艾滋病毒感染者丙型肝炎微消除状况——中欧和东欧网络组欧洲指南数据

IF 1.7 Q3 INFECTIOUS DISEASES
GERMS Pub Date : 2025-06-30 eCollection Date: 2025-06-01 DOI:10.18683/germs.2025.1464
Agata Skrzat-Klapaczyńska, Sergii Antoniak, Svitlana Antonyak, Konstantinos Protopapas, Antonios Papadopoulos, Daniela Maric, Botond Lakatos, Antonija Verhaz, Milan Zlamal, Zofia Bartovska, Milena Stefanovikj, Gordana Dragovic, Arjan Harxhi, David Jilich, Kerstin Aimla, Lilia Cojuhari, Justyna Kowalska, Josip Begovac
{"title":"2022年中欧和东欧艾滋病毒感染者丙型肝炎微消除状况——中欧和东欧网络组欧洲指南数据","authors":"Agata Skrzat-Klapaczyńska, Sergii Antoniak, Svitlana Antonyak, Konstantinos Protopapas, Antonios Papadopoulos, Daniela Maric, Botond Lakatos, Antonija Verhaz, Milan Zlamal, Zofia Bartovska, Milena Stefanovikj, Gordana Dragovic, Arjan Harxhi, David Jilich, Kerstin Aimla, Lilia Cojuhari, Justyna Kowalska, Josip Begovac","doi":"10.18683/germs.2025.1464","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The implementation of nationwide viral hepatitis C elimination programs is challenging in Central and Eastern European countries (CEEC). It is reasonable to start by targeting specific populations, such as people living with HIV (PLWH), who are at higher risk of acquiring HCV or developing HCV-related complications.</p><p><strong>Methods: </strong>Euroguidelines in Central and Eastern Europe Network Group consists of experts in the field of infectious diseases from 26 countries in the region. Between April 26<sup>th</sup> and June 23<sup>rd</sup> 2023, the group performed an on-line survey consisting of 32 questions. The questionnaire assessed the status of HCV micro-elimination in 2022.</p><p><strong>Results: </strong>Twelve HIV centers from 11 countries responded: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Greece, Hungary, Macedonia, Moldova, Serbia and Ukraine. All centers screen for HCV antibody all PLWH at entry into care. The seroprevalence of anti-HCV was <5% in 5 centers (Albania, Croatia, Serbia, North Macedonia and Hungary), 30.2% in Estonia and 29% in Ukraine, Greece and Moldova had high seroprevalence as well, 15.3% and 15.6% respectively. The prevalence of HCV viremia in antibody-positive PLWH was very high in Greece (85%), while in most other treatment centers it ranged from 4.2% to 38.2%. There is also a screening policy of annual HCV-testing of HCV-antibody negative persons in all centers by either testing all PLWH or those considered at risk. Direct-acting antiviral agents (DAA) were not available in one country (Albania). Among PLWH who entered care in 2022, nine out of 12 ECEE centers reported cases of HCV/HIV coinfection, with five centers indicating that at least 50% of these individuals were HCV-viremic.</p><p><strong>Conclusions: </strong>HCV screening in PLWH followed by access to DAA treatments were available in all but one center. Microelimination of HCV in PLWH in the majority of surveyed HIV treatment centers in CEEC has not been achieved and efforts to reach this goal need to be strengthened.</p>","PeriodicalId":45107,"journal":{"name":"GERMS","volume":"15 2","pages":"144-156"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12424253/pdf/","citationCount":"0","resultStr":"{\"title\":\"The status of hepatitis C microelimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group.\",\"authors\":\"Agata Skrzat-Klapaczyńska, Sergii Antoniak, Svitlana Antonyak, Konstantinos Protopapas, Antonios Papadopoulos, Daniela Maric, Botond Lakatos, Antonija Verhaz, Milan Zlamal, Zofia Bartovska, Milena Stefanovikj, Gordana Dragovic, Arjan Harxhi, David Jilich, Kerstin Aimla, Lilia Cojuhari, Justyna Kowalska, Josip Begovac\",\"doi\":\"10.18683/germs.2025.1464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The implementation of nationwide viral hepatitis C elimination programs is challenging in Central and Eastern European countries (CEEC). It is reasonable to start by targeting specific populations, such as people living with HIV (PLWH), who are at higher risk of acquiring HCV or developing HCV-related complications.</p><p><strong>Methods: </strong>Euroguidelines in Central and Eastern Europe Network Group consists of experts in the field of infectious diseases from 26 countries in the region. Between April 26<sup>th</sup> and June 23<sup>rd</sup> 2023, the group performed an on-line survey consisting of 32 questions. The questionnaire assessed the status of HCV micro-elimination in 2022.</p><p><strong>Results: </strong>Twelve HIV centers from 11 countries responded: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Greece, Hungary, Macedonia, Moldova, Serbia and Ukraine. All centers screen for HCV antibody all PLWH at entry into care. The seroprevalence of anti-HCV was <5% in 5 centers (Albania, Croatia, Serbia, North Macedonia and Hungary), 30.2% in Estonia and 29% in Ukraine, Greece and Moldova had high seroprevalence as well, 15.3% and 15.6% respectively. The prevalence of HCV viremia in antibody-positive PLWH was very high in Greece (85%), while in most other treatment centers it ranged from 4.2% to 38.2%. There is also a screening policy of annual HCV-testing of HCV-antibody negative persons in all centers by either testing all PLWH or those considered at risk. Direct-acting antiviral agents (DAA) were not available in one country (Albania). Among PLWH who entered care in 2022, nine out of 12 ECEE centers reported cases of HCV/HIV coinfection, with five centers indicating that at least 50% of these individuals were HCV-viremic.</p><p><strong>Conclusions: </strong>HCV screening in PLWH followed by access to DAA treatments were available in all but one center. Microelimination of HCV in PLWH in the majority of surveyed HIV treatment centers in CEEC has not been achieved and efforts to reach this goal need to be strengthened.</p>\",\"PeriodicalId\":45107,\"journal\":{\"name\":\"GERMS\",\"volume\":\"15 2\",\"pages\":\"144-156\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12424253/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GERMS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18683/germs.2025.1464\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GERMS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18683/germs.2025.1464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

在中欧和东欧国家(CEEC)实施全国性的病毒性丙型肝炎消除计划具有挑战性。从针对特定人群开始是合理的,例如艾滋病毒感染者(PLWH),他们获得丙型肝炎病毒或发生丙型肝炎相关并发症的风险较高。方法:欧洲指南中欧和东欧网络小组由来自该区域26个国家传染病领域的专家组成。在2023年4月26日至6月23日期间,该小组进行了一项包含32个问题的在线调查。该问卷评估了2022年HCV微消除状况。结果:来自11个国家的12个艾滋病中心做出了回应:阿尔巴尼亚、波斯尼亚和黑塞哥维那、克罗地亚、捷克共和国、爱沙尼亚、希腊、匈牙利、马其顿、摩尔多瓦、塞尔维亚和乌克兰。所有中心在进入护理时对所有PLWH进行HCV抗体筛查。结论:在PLWH中进行HCV筛查后,除一个中心外,所有中心均可获得DAA治疗。在中东欧国家大多数接受调查的艾滋病毒治疗中心,艾滋病病毒感染者的微消除尚未实现,实现这一目标的努力需要加强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The status of hepatitis C microelimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group.

Introduction: The implementation of nationwide viral hepatitis C elimination programs is challenging in Central and Eastern European countries (CEEC). It is reasonable to start by targeting specific populations, such as people living with HIV (PLWH), who are at higher risk of acquiring HCV or developing HCV-related complications.

Methods: Euroguidelines in Central and Eastern Europe Network Group consists of experts in the field of infectious diseases from 26 countries in the region. Between April 26th and June 23rd 2023, the group performed an on-line survey consisting of 32 questions. The questionnaire assessed the status of HCV micro-elimination in 2022.

Results: Twelve HIV centers from 11 countries responded: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Greece, Hungary, Macedonia, Moldova, Serbia and Ukraine. All centers screen for HCV antibody all PLWH at entry into care. The seroprevalence of anti-HCV was <5% in 5 centers (Albania, Croatia, Serbia, North Macedonia and Hungary), 30.2% in Estonia and 29% in Ukraine, Greece and Moldova had high seroprevalence as well, 15.3% and 15.6% respectively. The prevalence of HCV viremia in antibody-positive PLWH was very high in Greece (85%), while in most other treatment centers it ranged from 4.2% to 38.2%. There is also a screening policy of annual HCV-testing of HCV-antibody negative persons in all centers by either testing all PLWH or those considered at risk. Direct-acting antiviral agents (DAA) were not available in one country (Albania). Among PLWH who entered care in 2022, nine out of 12 ECEE centers reported cases of HCV/HIV coinfection, with five centers indicating that at least 50% of these individuals were HCV-viremic.

Conclusions: HCV screening in PLWH followed by access to DAA treatments were available in all but one center. Microelimination of HCV in PLWH in the majority of surveyed HIV treatment centers in CEEC has not been achieved and efforts to reach this goal need to be strengthened.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
GERMS
GERMS INFECTIOUS DISEASES-
CiteScore
2.80
自引率
5.00%
发文量
36
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信